OSE Immunotherapeutics SA announced that the trial’s Independent Drug Safety Monitoring Board provided a positive recommendation on the continuation until its completion of the Phase 2 clinical trial of IL-7 Receptor antagonist Lusvertikimab in ulcerative colitis.
